Crossmark

SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment

Crossref DOI link: https://doi.org/10.1016/j.reumae.2022.03.004

Published Print: 2022-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Narváez, Javier https://orcid.org/0000-0002-1614-8064
Díaz del Campo Fontecha, Petra

Brito García, Noé

Bonilla, Gema

Aburto, Myriam

Castellví, Iván

Cano-Jiménez, Esteban

Mena-Vázquez, Natalia

Nieto, M. Asunción

Ortiz, Ana María

Valenzuela, Claudia

Abad Hernández, Miguel Ángel

Castrejón, Isabel

Correyero Plaza, María

Francisco Hernández, Félix Manuel

Hernández Hernández, María Vanesa

Rodríquez Portal, José Antonio
Funding

Funding for this research was provided by:

Bristol-Myers Squibb

Chiesi Farmaceutici

Gilead Sciences

Sociedad Española de Neumología y Cirugía Torácica

Eli Lilly and Company

Janssen Pharmaceuticals

Actelion Pharmaceuticals

Sociedad Española de Reumatología

Pfizer

UCB

Teva Pharmaceutical Industries

Novartis

Sandoz

AbbVie

GlaxoSmithKline España

Meso Scale Diagnostics

Sanofi

Roche España

Roche
License Information

Text and Data Mining valid from 2022-11-01

Text and Data Mining valid from 2022-11-01
More Information

This article is maintained by: Elsevier

Article Title: SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2022.03.004

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2022.03.005

Content Type: article

Copyright: © 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Document is current

Any future updates will be listed below